SIGLEC1 and breast cancer: To investigate the prognostic value of CD169+ macrophages in breast cancer, we first compared their density in RLNs to that of CD8+ CTLs in resected primary tumors (Fig 1A) of paired patient samples, and then determined their correlation with clinicopathological features.